YOU ARE HERE: LAT HomeCollectionsGeron Corp

Geron Corp

April 2, 2003 | From Times Wire Services
Shares of struggling Geron Corp. skyrocketed 28% on Tuesday after it published research indicating that it could produce liver cells from stem cells in a way that may help scientists test drugs for liver toxicity. In the journal Cell Transplantation, the biotech company described how its scientists produce hepatocytes, the basic functional cells of the liver, from human embryonic stem cells. Hepatocytes have multiple characteristics, including the ability to metabolize enzymes.
July 19, 2005 | From Reuters
Biotech company Geron Corp. said Monday that it had signed a licensing deal with drug maker Merck & Co. to develop a cancer vaccine that targets an enzyme linked to tumor growth, sending Geron shares up 27%. Under the terms of the agreement, Geron will receive an upfront payment, milestone payments upon achievement of certain development and regulatory events, and royalties. Specific terms were not disclosed.
The owner of key patents on embryonic stem cells is suing Geron Corp. to prevent it from controlling commercial development of the cells. The lawsuit is a harbinger of the intellectual property battles likely to ensue in stem cell research. Wisconsin Alumni Research Foundation said it filed the suit in federal court late Monday to ensure that scientists and companies have broad access to stem cell technology and five cell lines developed at the University of Wisconsin.
The stock of a small California biotechnology firm, Geron Corp., climbed to record levels Friday on news that company-backed scientists have grown human stem cells in the laboratory--a discovery hailed as a first step toward producing transplant organs on demand. The Menlo Park, Calif.-based company financed the university research and has licensed the technology, which made front-page headlines this week and was featured on news programs throughout the country.
June 11, 2003 | Denise Gellene, Times Staff Writer
Shares in Geron Corp. rose nearly 15% on Tuesday after the small biotech company said it received a patent that could give it an advantage in the race to produce medicines from human embryonic stem cells. The Menlo Park-based firm's shares closed at $7.98, up $1.02, on Nasdaq, after hitting a 52-week high of $9.75 earlier in the day. Embryonic stem cells are formed in the earliest weeks of pregnancy and are capable of turning into any of the 300 cell types in the body.
In one laboratory hallway at Geron Corp., a Bay Area biotech firm, are photos of the scientists rafting down a river together and dancing at a Christmas party. A poster advertises a company ski trip. Then, in another hallway, a different side of life there is revealed in pictures taken last summer during a round-the-clock race with competing labs to pinpoint a hotly pursued gene. A shot of the parking lot one Saturday shows cars aplenty. Desks sag under data printouts.
May 4, 2011 | By Eryn Brown, Los Angeles Times
On Wednesday morning the California Institute for Regenerative Medicine announced a $25-million award to support a spinal cord injury trial.  It is the first time that the $3-billion state stem cell funding agency has backed a human clinical trial.  As expected by observers, the award is a loan to Geron Corp., a Menlo Park, Calif.-based biopharmaceuticals firm that has been working on a treatment for spinal cord injuries that is derived from...
October 11, 2010
Make way for the future, at least when it comes to stem-cell therapy. An Atlanta hospital treated the first patient Friday in a nationwide clinical trial of a therapy derived from embryonic stem cells. The clinical trial, run by pharmaceutical company Geron Corp., seeks to test whether experimental cells, known as GRNOPC1, are safe for use in humans and whether patients will regain neuromuscular control in their legs and torsos. The Shepherd Center in Atlanta, a rehabilitation hospital that specializes in people who have spinal cord injuries or disease, and Northwestern Medicine in Chicago are currently enrolling patients in the trial.
November 21, 2011 | By Eryn Brown, Los Angeles Times
For patients paralyzed by spinal cord injuries, Geron Corp.'s stem cell research was the shining hope. The biotech firm showered scientists with millions of dollars to develop a treatment to reverse spinal damage. The therapy was the first treatment derived from embryonic stem cells to be cleared by the Food and Drug Administration for testing in humans. But last week, Geron abruptly pulled the plug on its pioneering trial and the rest of its stem cell business, including early work on treatments for heart ailments, diabetes and other diseases.
Los Angeles Times Articles